Efficacy and Safety of VB119 in Subjects With Membranous Nephropathy
Status:
Recruiting
Trial end date:
2023-10-01
Target enrollment:
Participant gender:
Summary
This study is a Phase 1b/2a, open-label, sequential-cohort, dose escalation, and dose
expansion study to evaluate the safety, tolerability, PK, and PD of VB119 in subjects with
primary MN